17
Feb
2020
Tag: drug development
3
Feb
2020
Bionest
Nobel Prize in Medicine Goes to Oxygen-Sensing Research
How cells sense and adapt to oxygen availability plays an important role in anemia, cancer, stroke, infection, wound healing, and myocardial infarction.
23
Dec
2019
Bionest
The SMA Market: Assessing the Unknowns
Challenges and opportunities in the field of spinal muscular atrophy, including how new disease-modifying therapies are likely to change SMA’s course over time.
9
Dec
2019
Bionest
First Peanut Allergy Immunotherapeutic Recommended for FDA Approval
No standardized oral immunotherapeutics have existed for peanut allergies. Could this soon change?
2
Dec
2019
Bionest
The Relationship Between ICER and Industry is Evolving
ICER is expected to update the assessment framework underpinning its evidence reports on new drugs and health care interventions at the end of this year. What changes are likely to be made?
25
Nov
2019
Bionest
Driving CAR-T beyond oncology
Several companies and research institutions are developing potential CAR-T treatments for non-cancer indications, from heart disease to viral infection.
4
Nov
2019
Bionest
Psychedelic Drug Research Making a Comeback
In the 1950s and early 1960s, researchers within both academic and governmental institutions extensively investigated the clinical potential of psychedelic drugs, notably both LSD and psilocybin, the psychoactive substance in “magic mushrooms.” This early research aimed to understand the biological underpinnings of schizophrenia and to find new treatments for psychological disorders such as depression, anxiety...
21
Oct
2019
Bionest
New Strategies Against a Hard-to-Treat Killer — Pancreatic Cancer
Pancreatic cancer was the third leading cause of cancer-related death in the United States in 2018. This year, experts estimate that 56,770 new cases will be diagnosed and 45,750 deaths will be recorded. Pancreatic cancer is especially lethal because in its early stages, when the disease is easiest to treat, patients are usually asymptomatic. The disease...
7
Oct
2019
Bionest
New Approvals for Tumor-Agnostic Cancer Treatments — and the Questions They Raise
On August 15, the U.S. Food and Drug Administration granted accelerated approval to Genentech/Roche’s Rozlytrek (entrectinib) for the treatment of adult and adolescent patients with solid tumors that exhibit neurotrophic tyrosine receptor kinase (NTRK) fusions and for whom there are no existing effective treatments. While NTRK fusions are rare, appearing in about 1% of solid...
23
Sep
2019